ANAGENICS LIMITED - Announcements

0.00%

0.7¢

Market Cap $3.474M

Consumer Defensive Household & Personal Products

Anagenics Limited is an Australia-based health and beauty-tech company that operates... Anagenics Limited is an Australia-based health and beauty-tech company that operates health wellness and beauty business servicing wholesale and retail customers through omnichannel, offering premium branded products. The Company operates through its holding entity, Anagenics Limited and its main operating subsidiary company BLC Cosmetics Pty Limited (BLC) being a distributor of prestige beauty cosmetics and beauty equipment. BLC is an importer and distributor of prestige international and local skin care and wellbeing brands, namely Thalgo, Comfort Zone, Priori and other premium brands. BLC services over 1,000 spas, clinics, salons, retail stores and online in Australia, New Zealand and the Pacific Islands. The Company's brands consist of evolis and Uspa. Evolis is an anti-ageing hair care collection focused on harnessing the scientific research to give customers' thicker and healthier hair.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

AN1	CELLMID RECORDS HIGHEST EVER QUARTERLY SALES FOR EVOLIS-CDY.AX	PRICE SENSITIVE	10/10/16	99.24KB	Share
AN1	Midkine Antibodies Show Anti-Tumor Activity In Brain Cancer-CDY.AX	PRICE SENSITIVE	05/10/16	110.64KB	Share
AN1	European Midkine Patent For Surgical Adhesion Allowed-CDY.AX	PRICE SENSITIVE	22/09/16	83.58KB	Share
AN1	Appendix 4E and Preliminary Final Report-CDY.AX	PRICE SENSITIVE	30/08/16	705.08KB	Share
AN1	New Publication for Cellmid's Midkine Antibody-CDY.AX	PRICE SENSITIVE	09/08/16	116.66KB	Share
AN1	Transcript of Cellmid Investor Briefing Call-CDY.AX	PRICE SENSITIVE	29/07/16	69.69KB	Share
AN1	Appendix 4C - quarterly-CDY.AX	PRICE SENSITIVE	26/07/16	185.34KB	Share
AN1	Ikon Legal Action,WPP-CDY.AX	PRICE SENSITIVE	22/07/16	66.88KB	Share
AN1	USA Distribution Partnership for Cellmid's Evolis-CDY.AX	PRICE SENSITIVE	20/07/16	116.87KB	Share
AN1	MK antibody publication and patent in bone healing-CDY.AX	PRICE SENSITIVE	24/06/16		Share
AN1	MK antibody publication and patent in bone healing-CDY.AX	PRICE SENSITIVE	24/06/16	113.86KB	Share
AN1	Appendix 4C - quarterly-CDY.AX	PRICE SENSITIVE	21/04/16	183KB	Share
AN1	Midkine Strategy Update-CDY.AX	PRICE SENSITIVE	08/04/16	83.56KB	Share
AN1	Cellmid to Refinance RnD Loan	PRICE SENSITIVE	26/02/16	84.44KB	Share
AN1	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	25/02/16	1.68MB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	27/01/16	151.53KB	Share
AN1	Cellmid receives $1.12M R&D Tax Credit	PRICE SENSITIVE	11/12/15	65.1KB	Share
AN1	Key Antibody Patent Granted in Europe	PRICE SENSITIVE	01/12/15	78.79KB	Share
AN1	Japanese Patent granted for use of Midkine for Hair Growth	PRICE SENSITIVE	24/11/15	97.57KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/15	331.63KB	Share
AN1	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	31/08/15	887.57KB	Share
AN1	Cellmid Launching Major Advertising Campaign	PRICE SENSITIVE	27/08/15	163.66KB	Share
AN1	Cellmid appoints EAS to support US Strategy	PRICE SENSITIVE	12/08/15	258.52KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/15	335.18KB	Share
AN1	Cellmid raises $4M to leverage sales growth	PRICE SENSITIVE	30/07/15	84.07KB	Share
AN1	Trading Halt	PRICE SENSITIVE	28/07/15	115.25KB	Share
AN1	Cellmid Revenue Guidance Upgrade	PRICE SENSITIVE	09/07/15	74.32KB	Share
AN1	US Patent for Anti-Midkine Antibodies Granted	PRICE SENSITIVE	29/06/15	101.52KB	Share
AN1	Cellmid Announces Brain Cancer Program	PRICE SENSITIVE	23/06/15	111.11KB	Share
AN1	Positive Toxicology Study Results for CAB102	PRICE SENSITIVE	15/06/15	103.32KB	Share
AN1	Cellmid Signs Agreement with Maywufa	PRICE SENSITIVE	02/06/15	84.22KB	Share
AN1	Cellmid Secures $1M Loan Funding	PRICE SENSITIVE	15/05/15	81.03KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/15	325.63KB	Share
AN1	Positive Clinical Results for Cellmid Hair Growth Product	PRICE SENSITIVE	15/04/15	106.11KB	Share
AN1	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	24/02/15	1.16MB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/15	282.08KB	Share
AN1	USA Patent Granted for Treatment of Heart Failure	PRICE SENSITIVE	21/01/15	88.64KB	Share
AN1	Australian Patent Granted for Use of Midkine for Hair Growth	PRICE SENSITIVE	12/01/15	97.82KB	Share
AN1	Key Midkine Antibody Patent Granted	PRICE SENSITIVE	15/12/14	75.9KB	Share
AN1	Cellmid Capital Raising	PRICE SENSITIVE	15/12/14	72.73KB	Share
AN1	Trading Halt	PRICE SENSITIVE	11/12/14	178.91KB	Share
AN1	Cellmid signs agreement with Zoetis	PRICE SENSITIVE	17/11/14	21.29KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	29/10/14	93.21KB	Share
AN1	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	29/08/14	406.37KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/14	91.69KB	Share
AN1	Cellmid Granted UK Patent for Use of Midkine for Hair Growth	PRICE SENSITIVE	16/07/14	29.37KB	Share
AN1	Landmark Study- FGF5 Critical Regulator of Human Hair Growth	PRICE SENSITIVE	15/07/14	31.41KB	Share
AN1	Quest Diagnostic License Update	PRICE SENSITIVE	20/06/14	28.46KB	Share
AN1	Manufacturing Partner Appointed by Cellmid	PRICE SENSITIVE	19/06/14	29.47KB	Share
AN1	Key Milestone Completed, Lead Antibody Selected	PRICE SENSITIVE	07/05/14	29.62KB	Share
AN1	Significant New Findings Presented at 3rd Midkine Symposium	PRICE SENSITIVE	30/04/14	28.98KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/14	90.15KB	Share
AN1	Appendix 4D and Half Yearly Accounts	PRICE SENSITIVE	27/02/14	310.73KB	Share
AN1	USA RNA/DNA Patent for Surgical Adhesion Allowed	PRICE SENSITIVE	10/02/14	29.96KB	Share
AN1	Chinese Distribution Agreement Signed for Hair Loss Products	PRICE SENSITIVE	29/01/14	29.17KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/14	101.46KB	Share
AN1	Results of Completed CK3000 Diagnostic Study	PRICE SENSITIVE	18/12/13	31.88KB	Share
AN1	Capital Raising of $2 million	PRICE SENSITIVE	11/12/13	47.67KB	Share
AN1	Trading Halt	PRICE SENSITIVE	09/12/13	52.95KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	23/10/13	91.23KB	Share
AN1	Key Antibody Patent Granted in Japan	PRICE SENSITIVE	18/10/13	316.4KB	Share
AN1	Key European Patent for Anti-Midkine Antibodies Granted	PRICE SENSITIVE	08/10/13	28.08KB	Share
AN1	R&D Tax Refund Received	PRICE SENSITIVE	04/10/13	21.09KB	Share
AN1	Midkine antibodies effective in cancer	PRICE SENSITIVE	03/10/13	28.4KB	Share
AN1	Cellmid Signs Major Japanese Distribution Agreement	PRICE SENSITIVE	20/09/13	23.07KB	Share
AN1	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	28/08/13	679.73KB	Share
AN1	Cellmid Received Pacific Edge Milestone Shares	PRICE SENSITIVE	01/08/13	28.81KB	Share
AN1	Cellmid Collaborates on Early Diagnosis of Colorectal Cancer	PRICE SENSITIVE	29/07/13	28.92KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/13	101.33KB	Share
AN1	Fujikura Exercises Option To License Cellmid Diagnostics	PRICE SENSITIVE	18/07/13	28.66KB	Share
AN1	Advangen Acquisition	PRICE SENSITIVE	08/05/13	33.77KB	Share
AN1	Trading Halt	PRICE SENSITIVE	06/05/13	58.72KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	22/04/13	96.39KB	Share
AN1	Cellmid Diagnostic Licenses Update	PRICE SENSITIVE	26/03/13	32.65KB	Share
AN1	Cellmid Completes $2M Placement	PRICE SENSITIVE	13/03/13	24.5KB	Share
AN1	Trading Halt	PRICE SENSITIVE	11/03/13	58.6KB	Share
AN1	Response to ASX Price Query	PRICE SENSITIVE	08/03/13	167.83KB	Share
AN1	Response to ASX Price Query	PRICE SENSITIVE	27/02/13	166.92KB	Share
AN1	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	15/02/13	193.97KB	Share
AN1	Cellmid Signs Midkine Diagnostic Agreement	PRICE SENSITIVE	11/02/13	28.02KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/13	96.49KB	Share
AN1	Positive Data in Midkine Antibody Study in Kidney Disease	PRICE SENSITIVE	23/01/13	127.62KB	Share
AN1	Response to ASX Aware Query	PRICE SENSITIVE	22/01/13	182.07KB	Share
AN1	EU Patent Allowed for Treating Vascular Occlusive Disease	PRICE SENSITIVE	21/01/13	28KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	22/10/12	94.76KB	Share
AN1	$748K R&D Tax Credit Received	PRICE SENSITIVE	02/10/12	20.36KB	Share
AN1	Underwritten Non-Renounceable Pro-Rata Offer and Placement	PRICE SENSITIVE	14/09/12	308.55KB	Share
AN1	Evolis Hair Growth Products Exceed Distribution Targets	PRICE SENSITIVE	13/09/12	27.36KB	Share
AN1	Exclusive Distributor Appointed for evolis	PRICE SENSITIVE	04/09/12	23.43KB	Share
AN1	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	30/08/12	605.71KB	Share
AN1	Response to ASX Query	PRICE SENSITIVE	27/07/12	134.8KB	Share
AN1	Midkine Ischemia Patent Allowed in US	PRICE SENSITIVE	26/07/12	26.91KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	23/07/12	80.91KB	Share
AN1	Evolis to be Sold in Terry White Chemist Outlets	PRICE SENSITIVE	30/05/12	24.99KB	Share
AN1	Treg Antibody Patent Allowed in USA	PRICE SENSITIVE	07/05/12	234.07KB	Share
AN1	Appendix 4C - quarterly	PRICE SENSITIVE	26/04/12	99.04KB	Share
AN1	Cellmid Completes $1.5M Placement	PRICE SENSITIVE	24/04/12	24.5KB	Share
AN1	Trading Halt	PRICE SENSITIVE	23/04/12	58KB	Share
AN1	USA Antibody Patent for Adhesion Allowed	PRICE SENSITIVE	18/04/12	28.04KB	Share
AN1	Media Launch of Evolis Hair Products	PRICE SENSITIVE	29/03/12	50.12KB	Share

AN1 CELLMID RECORDS HIGHEST EVER QUARTERLY SALES FOR EVOLIS-CDY.AX
10/10/16	PRICE SENSITIVE	99.24KB	Share
AN1 Midkine Antibodies Show Anti-Tumor Activity In Brain Cancer-CDY.AX
05/10/16	PRICE SENSITIVE	110.64KB	Share
AN1 European Midkine Patent For Surgical Adhesion Allowed-CDY.AX
22/09/16	PRICE SENSITIVE	83.58KB	Share
AN1 Appendix 4E and Preliminary Final Report-CDY.AX
30/08/16	PRICE SENSITIVE	705.08KB	Share
AN1 New Publication for Cellmid's Midkine Antibody-CDY.AX
09/08/16	PRICE SENSITIVE	116.66KB	Share
AN1 Transcript of Cellmid Investor Briefing Call-CDY.AX
29/07/16	PRICE SENSITIVE	69.69KB	Share
AN1 Appendix 4C - quarterly-CDY.AX
26/07/16	PRICE SENSITIVE	185.34KB	Share
AN1 Ikon Legal Action,WPP-CDY.AX
22/07/16	PRICE SENSITIVE	66.88KB	Share
AN1 USA Distribution Partnership for Cellmid's Evolis-CDY.AX
20/07/16	PRICE SENSITIVE	116.87KB	Share
AN1 MK antibody publication and patent in bone healing-CDY.AX
24/06/16	PRICE SENSITIVE		Share
AN1 MK antibody publication and patent in bone healing-CDY.AX
24/06/16	PRICE SENSITIVE	113.86KB	Share
AN1 Appendix 4C - quarterly-CDY.AX
21/04/16	PRICE SENSITIVE	183KB	Share
AN1 Midkine Strategy Update-CDY.AX
08/04/16	PRICE SENSITIVE	83.56KB	Share
AN1 Cellmid to Refinance RnD Loan
26/02/16	PRICE SENSITIVE	84.44KB	Share
AN1 Appendix 4D and Half Year Accounts
25/02/16	PRICE SENSITIVE	1.68MB	Share
AN1 Appendix 4C - quarterly
27/01/16	PRICE SENSITIVE	151.53KB	Share
AN1 Cellmid receives $1.12M R&D Tax Credit
11/12/15	PRICE SENSITIVE	65.1KB	Share
AN1 Key Antibody Patent Granted in Europe
01/12/15	PRICE SENSITIVE	78.79KB	Share
AN1 Japanese Patent granted for use of Midkine for Hair Growth
24/11/15	PRICE SENSITIVE	97.57KB	Share
AN1 Appendix 4C - quarterly
27/10/15	PRICE SENSITIVE	331.63KB	Share
AN1 Appendix 4E and Preliminary Final Report
31/08/15	PRICE SENSITIVE	887.57KB	Share
AN1 Cellmid Launching Major Advertising Campaign
27/08/15	PRICE SENSITIVE	163.66KB	Share
AN1 Cellmid appoints EAS to support US Strategy
12/08/15	PRICE SENSITIVE	258.52KB	Share
AN1 Appendix 4C - quarterly
30/07/15	PRICE SENSITIVE	335.18KB	Share
AN1 Cellmid raises $4M to leverage sales growth
30/07/15	PRICE SENSITIVE	84.07KB	Share
AN1 Trading Halt
28/07/15	PRICE SENSITIVE	115.25KB	Share
AN1 Cellmid Revenue Guidance Upgrade
09/07/15	PRICE SENSITIVE	74.32KB	Share
AN1 US Patent for Anti-Midkine Antibodies Granted
29/06/15	PRICE SENSITIVE	101.52KB	Share
AN1 Cellmid Announces Brain Cancer Program
23/06/15	PRICE SENSITIVE	111.11KB	Share
AN1 Positive Toxicology Study Results for CAB102
15/06/15	PRICE SENSITIVE	103.32KB	Share
AN1 Cellmid Signs Agreement with Maywufa
02/06/15	PRICE SENSITIVE	84.22KB	Share
AN1 Cellmid Secures $1M Loan Funding
15/05/15	PRICE SENSITIVE	81.03KB	Share
AN1 Appendix 4C - quarterly
29/04/15	PRICE SENSITIVE	325.63KB	Share
AN1 Positive Clinical Results for Cellmid Hair Growth Product
15/04/15	PRICE SENSITIVE	106.11KB	Share
AN1 Appendix 4D and Half Year Accounts
24/02/15	PRICE SENSITIVE	1.16MB	Share
AN1 Appendix 4C - quarterly
28/01/15	PRICE SENSITIVE	282.08KB	Share
AN1 USA Patent Granted for Treatment of Heart Failure
21/01/15	PRICE SENSITIVE	88.64KB	Share
AN1 Australian Patent Granted for Use of Midkine for Hair Growth
12/01/15	PRICE SENSITIVE	97.82KB	Share
AN1 Key Midkine Antibody Patent Granted
15/12/14	PRICE SENSITIVE	75.9KB	Share
AN1 Cellmid Capital Raising
15/12/14	PRICE SENSITIVE	72.73KB	Share
AN1 Trading Halt
11/12/14	PRICE SENSITIVE	178.91KB	Share
AN1 Cellmid signs agreement with Zoetis
17/11/14	PRICE SENSITIVE	21.29KB	Share
AN1 Appendix 4C - quarterly
29/10/14	PRICE SENSITIVE	93.21KB	Share
AN1 Appendix 4E and Preliminary Final Report
29/08/14	PRICE SENSITIVE	406.37KB	Share
AN1 Appendix 4C - quarterly
29/07/14	PRICE SENSITIVE	91.69KB	Share
AN1 Cellmid Granted UK Patent for Use of Midkine for Hair Growth
16/07/14	PRICE SENSITIVE	29.37KB	Share
AN1 Landmark Study- FGF5 Critical Regulator of Human Hair Growth
15/07/14	PRICE SENSITIVE	31.41KB	Share
AN1 Quest Diagnostic License Update
20/06/14	PRICE SENSITIVE	28.46KB	Share
AN1 Manufacturing Partner Appointed by Cellmid
19/06/14	PRICE SENSITIVE	29.47KB	Share
AN1Key Milestone Completed, Lead Antibody Selected
07/05/14	PRICE SENSITIVE	29.62KB	Share
AN1Significant New Findings Presented at 3rd Midkine Symposium
30/04/14	PRICE SENSITIVE	28.98KB	Share
AN1Appendix 4C - quarterly
28/04/14	PRICE SENSITIVE	90.15KB	Share
AN1Appendix 4D and Half Yearly Accounts
27/02/14	PRICE SENSITIVE	310.73KB	Share
AN1USA RNA/DNA Patent for Surgical Adhesion Allowed
10/02/14	PRICE SENSITIVE	29.96KB	Share
AN1Chinese Distribution Agreement Signed for Hair Loss Products
29/01/14	PRICE SENSITIVE	29.17KB	Share
AN1Appendix 4C - quarterly
28/01/14	PRICE SENSITIVE	101.46KB	Share
AN1Results of Completed CK3000 Diagnostic Study
18/12/13	PRICE SENSITIVE	31.88KB	Share
AN1Capital Raising of $2 million
11/12/13	PRICE SENSITIVE	47.67KB	Share
AN1Trading Halt
09/12/13	PRICE SENSITIVE	52.95KB	Share
AN1Appendix 4C - quarterly
23/10/13	PRICE SENSITIVE	91.23KB	Share
AN1Key Antibody Patent Granted in Japan
18/10/13	PRICE SENSITIVE	316.4KB	Share
AN1Key European Patent for Anti-Midkine Antibodies Granted
08/10/13	PRICE SENSITIVE	28.08KB	Share
AN1R&D Tax Refund Received
04/10/13	PRICE SENSITIVE	21.09KB	Share
AN1Midkine antibodies effective in cancer
03/10/13	PRICE SENSITIVE	28.4KB	Share
AN1Cellmid Signs Major Japanese Distribution Agreement
20/09/13	PRICE SENSITIVE	23.07KB	Share
AN1Appendix 4E and Preliminary Final Report
28/08/13	PRICE SENSITIVE	679.73KB	Share
AN1Cellmid Received Pacific Edge Milestone Shares
01/08/13	PRICE SENSITIVE	28.81KB	Share
AN1Cellmid Collaborates on Early Diagnosis of Colorectal Cancer
29/07/13	PRICE SENSITIVE	28.92KB	Share
AN1Appendix 4C - quarterly
26/07/13	PRICE SENSITIVE	101.33KB	Share
AN1Fujikura Exercises Option To License Cellmid Diagnostics
18/07/13	PRICE SENSITIVE	28.66KB	Share
AN1Advangen Acquisition
08/05/13	PRICE SENSITIVE	33.77KB	Share
AN1Trading Halt
06/05/13	PRICE SENSITIVE	58.72KB	Share
AN1Appendix 4C - quarterly
22/04/13	PRICE SENSITIVE	96.39KB	Share
AN1Cellmid Diagnostic Licenses Update
26/03/13	PRICE SENSITIVE	32.65KB	Share
AN1Cellmid Completes $2M Placement
13/03/13	PRICE SENSITIVE	24.5KB	Share
AN1Trading Halt
11/03/13	PRICE SENSITIVE	58.6KB	Share
AN1Response to ASX Price Query
08/03/13	PRICE SENSITIVE	167.83KB	Share
AN1Response to ASX Price Query
27/02/13	PRICE SENSITIVE	166.92KB	Share
AN1Appendix 4D and Half Year Accounts
15/02/13	PRICE SENSITIVE	193.97KB	Share
AN1Cellmid Signs Midkine Diagnostic Agreement
11/02/13	PRICE SENSITIVE	28.02KB	Share
AN1Appendix 4C - quarterly
29/01/13	PRICE SENSITIVE	96.49KB	Share
AN1Positive Data in Midkine Antibody Study in Kidney Disease
23/01/13	PRICE SENSITIVE	127.62KB	Share
AN1Response to ASX Aware Query
22/01/13	PRICE SENSITIVE	182.07KB	Share
AN1EU Patent Allowed for Treating Vascular Occlusive Disease
21/01/13	PRICE SENSITIVE	28KB	Share
AN1Appendix 4C - quarterly
22/10/12	PRICE SENSITIVE	94.76KB	Share
AN1$748K R&D Tax Credit Received
02/10/12	PRICE SENSITIVE	20.36KB	Share
AN1Underwritten Non-Renounceable Pro-Rata Offer and Placement
14/09/12	PRICE SENSITIVE	308.55KB	Share
AN1Evolis Hair Growth Products Exceed Distribution Targets
13/09/12	PRICE SENSITIVE	27.36KB	Share
AN1Exclusive Distributor Appointed for evolis
04/09/12	PRICE SENSITIVE	23.43KB	Share
AN1Appendix 4E and Preliminary Final Report
30/08/12	PRICE SENSITIVE	605.71KB	Share
AN1Response to ASX Query
27/07/12	PRICE SENSITIVE	134.8KB	Share
AN1Midkine Ischemia Patent Allowed in US
26/07/12	PRICE SENSITIVE	26.91KB	Share
AN1Appendix 4C - quarterly
23/07/12	PRICE SENSITIVE	80.91KB	Share
AN1Evolis to be Sold in Terry White Chemist Outlets
30/05/12	PRICE SENSITIVE	24.99KB	Share
AN1Treg Antibody Patent Allowed in USA
07/05/12	PRICE SENSITIVE	234.07KB	Share
AN1Appendix 4C - quarterly
26/04/12	PRICE SENSITIVE	99.04KB	Share
AN1Cellmid Completes $1.5M Placement
24/04/12	PRICE SENSITIVE	24.5KB	Share
AN1Trading Halt
23/04/12	PRICE SENSITIVE	58KB	Share
AN1USA Antibody Patent for Adhesion Allowed
18/04/12	PRICE SENSITIVE	28.04KB	Share
AN1Media Launch of Evolis Hair Products
29/03/12	PRICE SENSITIVE	50.12KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $3.474M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	1544100	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	364754	3

View Market Depth

No.	Vol.	Price($)
2	1544100	0.006
1	750000	0.005
6	7665000	0.004
3	5450000	0.003
1	800000	0.002

Price($)	Vol.	No.
0.007	364754	3
0.008	653713	2
0.009	620000	2
0.010	500000	1
0.015	200000	1

Last trade - 16.21pm 08/08/2025 (20 minute delay)

AN1 (ASX) Chart

Day chart unavailable

ANAGENICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available